The “Active Pharmaceutical Ingredients CDMO Market Research Report by Drug, Synthesis, Product, Workflow, Application, and State – United States Forecast to 2026 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.
The United States Active Pharmaceutical Ingredients CDMO Market size was estimated at USD 25.28 billion in 2020, is expected to reach USD 28.98 billion in 2021, and is projected to grow at a CAGR of 11.87% reaching USD 49.56 billion by 2026.
Market Statistics
The report provides market sizing and forecast across five major currencies – USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Market Segmentation & Coverage
This research report categorizes the Active Pharmaceutical Ingredients CDMO to forecast the revenues and analyze the trends in each of the following sub-markets:
- Based on Drug, the market was studied across Generics and Innovative.
- Based on Synthesis, the market was studied across Biotech and Synthetic.
- Based on Product, the market was studied across Antibody Drug Conjugate (ADC), Highly Potent Active
- Pharmaceutical Ingredient (HP-API), and Traditional Active Pharmaceutical Ingredient (Traditional API).
- Based on Workflow, the market was studied across Clinical and Commercial.
- Based on Application, the market was studied across Cardiovascular, Diabetes, Glaucoma, Hormonal, and Oncology.
- Based on State, the market was studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.
Source: Business Wire